INVESTORS & MEDIA
Corporate Governance
Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
---|---|---|---|---|---|---|---|
Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 355 | $483.80 | 519,844 |
Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 345 | $484.72 | 519,499 |
Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 1,693 | $485.63 | 517,806 |
Mar 10, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 7 | $486.31 | 517,799 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 96,736 | -- | 150,000 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | -- | -- |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 96,736 | $30.63 | 614,535 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 50,545 | $476.42 | 563,990 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 150,000 | $30.63 | 713,990 |
Mar 09, 2020 |
Director, President and Chief Scientific
|
Director, President and Chief Scientific | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 78,376 | $476.42 | 635,614 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.